Singapore markets open in 4 hours 1 minute

Kronos Bio, Inc. (KRON)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.3400+0.0700 (+3.08%)
As of 03:59PM EST. Market open.

Kronos Bio, Inc.

1300 South El Camino Real
Suite 300
San Mateo, CA 94402
United States
650 781 5200

Full-time employees101

Key executives

NameTitlePayExercisedYear born
Dr. Norbert W. Bischofberger Ph.D.Pres, CEO & Director644.98kN/A1956
Mr. Joshua A. KazamCo-Founder & Director35kN/A1977
Dr. Yasir B. Al-Wakeel BCh, BM, MACFO & Head of Corp. Devel.789.29kN/A1982
Ms. Barbara A. Kosacz J.D.COO, Sec. & Gen. Counsel607.99kN/A1958
Dr. Christopher Dinsmore Ph.D.Chief Scientific Officer595.6k788.42k1967
Dr. Jorge F. DiMartino M.D., Ph.D.Chief Medical Officer & Exec. VP of Clinical Devel.640.21kN/A1964
Mr. Charles Lin Ph.D.Sr. VP of BiologyN/AN/AN/A
Dr. Elizabeth A. Olek D.O., M.P.H.Sr. VP of Clinical Devel.N/AN/A1965
Ms. Allison Frisbee J.D.Sr. VP & Deputy Gen. CounselN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of entospletinib in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, is a next-generation SYK inhibitor for treatment of autoimmune disease. Kronos Bio, Inc. was incorporated in 2017 and is headquartered in San Mateo, California.

Corporate governance

Kronos Bio, Inc.’s ISS governance QualityScore as of 1 February 2023 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.